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Abstract 
Importance 
Low vitamin D levels are associated with elevated blood pressure and future cardiovascular 
events. It is unclear if vitamin D supplementation reduces blood pressure, or which patient 
characteristics predict response. 
 
Objective 
To systematically review whether treatment with vitamin D or its analogs reduce blood 
pressure  
 
Data sources 
Medline, CINAHL, EMBASE, Cochrane Central Register of Controlled Trials and clinical 
trials.com, augmented by handsearching references from included articles and previous 
reviews. Google was searched for grey literature.  No language restrictions were applied.  The 
search period spanned 1966 to end March 2014 
 
Study selection 
Randomised placebo controlled trials, using vitamin D supplementation for a minimum of 4 
weeks for any indication, which reported blood pressure data. Studies were included if they 
used active or inactive forms of vitamin D or vitamin D analogs. Cointerventions were 
permitted if identical in all treatment arms. 
 
Data extraction and synthesis 
Data were extracted on baseline demographics, 25-hydroxyvitamin D levels, systolic and 
diastolic blood pressures and change in blood pressure between baseline and final follow up 
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timepoint. Individual patient data on age, sex, medication use, diabetes, baseline and follow up 
blood pressures and 25-hydroxyvitamin D levels were requested from authors of included 
studies. For trial level data, between-group differences in blood pressure change were 
combined in a random-effects model. For individual patient level data, between-group 
differences in blood pressure at final follow up, adjusted for baseline blood pressure levels, 
were calculated before combining in a random-effects model. 
 
Main outcomes and measures 
Difference in office systolic and diastolic blood pressure 
 
Results 
46 trials (n=4541) were included in the trial-level meta-analysis. Individual patient data were 
successfully obtained for 27 trials (n=3092). At trial level, no effect of vitamin D 
supplementation was seen on systolic blood pressure (0.0mmHg, 95%CI -0.8, 0.8; I2=21%) or 
diastolic blood pressure (-0.1mmHg; 95%CI -0.6, 0.5; I2=20%). Similar results were found 
analysing individual patient data (systolic -0.5mmHg; 95%CI -1.3, 0.4; I2=0%; diastolic 
0.2mmHg; 95%CI -0.3, 0.7; I2=0%). Subgroup analysis did not reveal any baseline factor 
predicting better response to therapy. 
 
Conclusions and relevance 
Vitamin D supplementation is ineffective as an agent for lowering blood pressure. 
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Introduction 
 
A wealth of observational data have demonstrated relationships between circulating vitamin D 
metabolite levels and blood pressure. Lower 25-hydroxyvitamin D (25OHD) levels are 
associated with higher blood pressure in cross-sectional studies1,2, and increased rates  of 
incident hypertension3. Such observations are underpinned by a number of biologically 
plausible mechanisms and the fact that vitamin D receptors are found on endothelial cells, 
smooth muscle cells and myocytes4. Vitamin D has been shown to improve endothelial 
function in some studies5,6, reduces the production of pro-inflammatory cytokines7, reduces 
parathyroid hormone levels (which is itself vasculotoxic) and reduces activity of the renin-
angiotension-aldosterone system8. Any or all of these mechanisms could therefore potentially 
mediate an effect of vitamin D on blood pressure.  
 
Intervention studies to date have thus far produced conflicting evidence on the blood pressure 
lowering effect of vitamin D. One previous meta-analysis9, based on a number of small trials, 
demonstrated a modest but significant decrease in blood pressure in studies where mean blood 
pressure was raised at baseline; another meta-analysis conducted at a similar time did not 
demonstrate a significant effect of vitamin D supplementation on blood pressure10 and a more 
recent meta-analysis11 showed a small decrease in diastolic, but not systolic blood pressure. 
Although effects of vitamin D on blood pressure appear small in previous meta-analyses, even 
a modest improvement in blood pressure would be of public health importance, as widespread 
supplementation with vitamin D would be an inexpensive intervention. Furthermore, it is 
possible that selected subgroups (for example non-white populations, those with very low 25-
hydroxyvitamin D levels) could benefit to a greater extent, potentially making vitamin D part 
of the therapeutic armamentarium in treating individuals with hypertension. 
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 In the five years since the first meta-analyses were published, there has been a proliferation in 
randomised controlled trials studying vitamin D and cardiovascular health.  We therefore 
sought to update our systematic review of randomised controlled trials to evaluate whether 
vitamin D supplementation reduces blood pressure when compared to placebo across a range 
of study populations and vitamin D analogs. We also sought to perform an individual patient 
data meta-analysis to further explore which subgroups of patients might potentially derive 
greatest benefit. 
 
 
Methods 
Review design 
We conducted a systematic review, based on a predefined protocol. The protocol was registered 
with the PROSPERO International Prospective Register of Systematic Reviews. 
(http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42012002816). We 
included randomised controlled trials which reported blood pressure or other measures of 
vascular function including arterial stiffness, endothelial function and left ventricular mass 
index within their outcomes.  Medline, CINAHL, EMBASE, Cochrane Central Register of 
Controlled Trials and clinicaltrials.com were searched using our search strategy.  We also 
searched for grey literature using Google, and hand searched references of included articles 
and references from previous reviews of vitamin D therapy.  No language restrictions were 
applied to eligible reports.  The search period spanned from 1966 to end March 2014 and was 
conducted by two of the authors (LAB and MDW).  
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 Search Strategy 
Search terms used were vitamin D, vitamin D3, vitamin D2, cholecalciferol, ergocalciferol, 
alphacalcidol, alfacalcidol, paricalcitol and doxercalciferol combined with blood pressure, 
hypertension, cardiovascular, mortality, randomized controlled trials or placebo. The electronic 
search strategy used for MEDLINE is given in the eAppendix. 
 
Study Selection 
We considered studies with participants with any baseline 25OHD level.  Studies with blood 
pressure reduction or changes in surrogate markers of cardiovascular risk were included; a 
minimum of 4 weeks therapy was necessary for inclusion in the review to ensure that the 
intervention had sufficient time to produce an effect. We included the following interventions: 
vitamin D2 (ergocalciferol), vitamin D3 (cholecalciferol), calcitriol (1, 25 hydroxyvitamin D3), 
1-alpha-vitamin D, paricalcitol and doxerocalciferol. Control groups receiving placebo were 
used and those receiving placebo plus co-intervention were included provided both arms of the 
study received the cointervention. Studies from both primary and secondary care or population 
settings were included.  We placed no restrictions on sex or ethnicity.  We did not include any 
studies recruiting participants less than 16 years old or studying patients on dialysis. 
 
The primary outcome of the meta-analysis was change in office systolic and diastolic blood 
pressure between baseline and follow up. 
 
Data extraction 
Two researchers (MDW, LAB) independently extracted data from all trial reports using data 
collection forms used in a previous systematic review9. Differences were resolved by 
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consensus. The following data were recorded for all eligible studies: sex, age, smoking status, 
social class, ethnic group/skin colour, functional status/dwelling place, diabetes status and 
glycosylated haemoglobin, kidney function, history of cardiovascular events, history of 
hypertension, baseline blood pressure, baseline use of angiotensin converting enzyme (ACE) 
inhibitors, angiotensin receptor blockers,  statins and aspirin. The following outcome measures 
were recorded for use in this analysis:  change in office blood pressure (systolic and diastolic), 
change in 24 hour blood pressure. Study authors were contacted to provide missing data or to 
clarify data unclear from primary reports. 
 
Individual patient data (IPD) collection:  
For all eligible studies, authors were approached to provide individual patient data in order to 
conduct subgroup analyses by baseline characteristics at patient level, in particular by baseline 
25OHD level, baseline medication use, baseline blood pressure and presence of diabetes 
mellitus. Data requested for each patient were: age, sex, body mass index (BMI), ethnicity, 
month of recruitment, systolic blood pressure at baseline and follow up, diastolic blood 
pressure at baseline and follow up, dose of vitamin D given (type, dose, frequency, duration), 
baseline 25OHD level (and follow up 25OHD level if available), baseline and post-treatment 
parathyroid hormone (PTH) and serum calcium/albumin, total cholesterol, high density 
lipoprotein (HDL) cholesterol, diagnosis of diabetes mellitus at baseline, diagnosis of previous 
stroke, myocardial infarction at baseline and whether patients were on ACE inhibitor, statin, 
angiotensin receptor antagonist at baseline.  
 
Risk of bias assessment 
Each included study was assessed for risk of bias using fields from the Delphi risk of bias 
checklist12 to assess the following parameters: quality of random allocation concealment, 
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intention to treat analysis, blinding of outcome assessors, treatment and control group 
comparability, inclusion and exclusion criteria clearly defined, participant blinding to 
allocation and description of withdrawals and dropouts. Funnel plots were generated to 
examine possible publication bias, supplemented by formal statistical testing using Egger’s 
test.  Study quality was assessed by two reviewers (MDW and LAB) independently, and 
discrepancies were resolved by consensus. 
 
Strategy for data synthesis 
Meta-analysis at trial level was performed using Comprehensive Meta-Analysis Software 
(Biostat, NJ, USA). Weighted squares method was used, using random effects models in all 
cases. For all treatment effects, a negative value denotes a reduction in blood pressure with 
intervention compared to placebo.  For each analysis at trial level, mean change between 
baseline and the last follow-up timepoint reported was compared between groups as these data 
were most commonly supplied in trial-level reports. For studies with more than one vitamin D 
group, the highest dose of vitamin D or analog was compared with the control group; 
intermediate dose groups were not analysed. Heterogeneity was assessed using the I2 test. Pre-
planned subgroup analyses were performed to examine effects of different preparations of 
vitamin D, dose ranges and baseline blood pressure. Degree of change in blood pressure was 
regressed against baseline blood pressure, trial duration, daily dose equivalent of vitamin D 
given and mean baseline 25OHD level. 
 
For individual patient data analysis, a two-stage analysis was performed, as recommended by 
Riley et al 13. For each study, the mean blood pressure values for each group at the final follow 
up timepoint were calculated, adjusted for baseline values using ANCOVA (SPSS v21, IBM, 
New York, USA). These values were then combined using weighted least-squares, random-
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effects models using RevMan 5.3 software (Cochrane Collaboration). For studies with more 
than one vitamin D dose, patients taking the highest dose were compared to placebo; patients 
taking the lower dose were excluded from analysis. A series of prespecified patient-level 
subgroup analyses were performed using these methods – diabetes mellitus vs no diabetes 
mellitus; ACE inhibitor vs no ACE inhibitor; baseline SBP above and below 140mmHg; DBP 
above and below 90mmHg, baseline PTH above and below the median level for the IPD 
dataset, and baseline 25OHD levels <25, 25-50 and >50nmol/L. For analyses of ACE inhibitor 
use, patients taking angiotensin receptor blockers were excluded from analysis given the 
similar, but not identical biological effect of these agents. Exploratory post-hoc analyses were 
undertaken for subgroups with combinations of risk factors (high blood pressure, low 25OHD 
levels and higher PTH levels), non-white participants, and summer versus winter enrolment; 
northern hemisphere summer was defined as June to August, and winter defined as December 
to February, with definitions inverted for southern hemisphere studies. 
 
Results 
Details of the search process are given in Figure 1. We included 52 studies in the systematic 
review; of these, 46 yielded data that could be combined in the trial-level meta-analysis. Six 
studies used mean arterial pressure, or reported median blood pressure readings and we were 
unable to obtain mean readings from the authors. We successfully obtained 27 datasets for 
individual patient data analysis. For the trials where we did not succeed in obtaining individual 
patient data, two author groups felt unable to share their data; one author group agreed but did 
not supply data; and in all other cases, authors did not respond to requests or could not be 
contacted. Details of all included studies are given in eTable 1. Six trials used 1-alpha 
hydroxylated vitamin D or calcitriol, four used paricalcitol, and the others used ergocalciferol 
or cholecalciferol. 
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 Quality assessment and publication bias 
Quality assessments, performed by assessing the risk of bias across a range of domains, are 
shown in eTable 2. Allocation concealment was deemed adequate in 51/52 trials, and most 
trials had adequate blinding for participants (49/52), other healthcare staff (49/52) and 
outcomes assessment (46/52). Only 22/52 trials clearly described analysis on intention to treat. 
Of the 30 trials where intention to treat was not well described, 19 trials clearly did not perform 
analyses on an intention to treat basis. Visual inspection of the funnel plot for systolic blood 
pressure treatment effect (see eFigure 1) revealed no obvious asymmetry to suggest publication 
bias; Egger’s test was not significant (p=0.62). 
 
Main outcome measures – trial level data 
Meta-analysis of change in blood pressure between baseline and final follow-up for each trial 
revealed no clinically or statistically significant effect on either systolic blood pressure 
(treatment effect 0.0mmHg, 95% CI -0.8 to 0.8; p=;0.97 I2=21%) or diastolic blood pressure 
(treatment effect -0.1mmHg, 95%CI -0.6 to 0.5; p=0.84; I2=20%). Forest plots for the overall 
effect of treatment on systolic and diastolic blood pressure are presented in Figure 2. 
Prespecified subgroup analyses are shown in Table 1; analysis by baseline blood pressure 
category, type of intervention, dose interval or baseline 25OHD category did not affect the 
results significantly. 
 
Trial-level metaregression 
No significant relationship was found at trial level between systolic blood pressure treatment 
effect and mean baseline systolic blood pressure (slope 0.016mmHg per mmHg baseline SBP, 
95% CI -0.037 to 0.069; p=0.55, see eFigure 2), baseline 25OHD level (slope 0.003mmHg per 
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nmol/L baseline 25OHD, 95% CI -0.014 to 0.021; p=0.70), baseline PTH level (slope -
0.009mmHg per pmol/L baseline PTH, 95% CI -0.036 to 0.053; p=0.53) or trial duration (slope 
0.007mmHg per month of trial, 95% CI -0.005 to 0.019; p=0.27). Similarly, for trials using 
vitamin D3, no significant relationship was found on metaregression between systolic blood 
pressure treatment effect and the daily dose equivalent used as treatment (slope -0.001mmHg 
per unit of vitamin D3, 95% CI -0.018 to 0.018; p=0.93). Small numbers of trials precluded 
metaregression of D2, paricalcitol or 1-alphacalcidol daily dose effects.  
 
Metaregression of diastolic treatment effect against baseline variables similarly showed no 
significant relationships: mean baseline diastolic blood pressure slope 0.001mmHg per mmHg 
baseline DBP (95% CI -0.003 to 0.006; p=0.54), baseline 25OHD level slope -0.001mmHg per 
nmol/L baseline 25OHD (95% CI -0.005 to 0.003; p=0.67), baseline PTH level slope -
0.020mmHg per pmol/L baseline PTH  (95% CI -0.051 to 0.011; p=0.21), trial duration slope 
0.007mmHg per month of trial, 95% CI -0.005 to 0.020; p=0.23) and daily dose equivalent 
slope 0.000mmHg per unit of vitamin D3 (95% CI 0.000 to 0.001; p=0.34). 
 
IPD analyses 
Analyses of the individual patient datasets are shown in Figure 3, with subgroup analyses 
shown in Table 2. The overall treatment effect derived from the IPD datasets was similar to 
that derived from the trial level data despite the use of a small number of trials (systolic blood 
pressure treatment effect -0.5mmHg, 95% CI -1.3 to 0.4, p=0.27, I2=0%; diastolic blood 
pressure treatment effect -0.2mmHg, 95%CI -0.7 to 0.3, p=0.38, I2=0%). In subgroup analyses, 
no significant differences were seen between patients with or without diabetes, taking or not 
taking ACE inhibitors, or by subgroups of baseline blood pressure, PTH or 25OHD (Table 2). 
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Analysis of the small group of patients with a combination of baseline factors potentially most 
likely to benefit (SBP>140mmHg, 25OHD<25nmol/L and PTH>4.8pmol) showed no evidence 
of benefit (n=60; treatment effect on systolic blood pressure 2.7mmHg, 95%CI -5.0 to 10.4, 
p=0.49; I2=0%). Similarly, analysis of participants of non-white ethnicity (n=214) showed no 
evidence of benefit (systolic BP treatment effect: 2.2mmHg, 95%CI -1.1 to 5.4; p=0.19; 
I2=28%; diastolic BP treatment effect: 0.4mmHg, 95%CI -1.7 to 2.6; p=0.70; I2=11%). 
Comparison of patients recruited during summer and winter months did not reveal any 
significant differences (systolic BP treatment effect for summer: -1.1mmHg, 95%CI -4.1 to 
2.0, p=0.50, I2=37; for winter: 1.3mmHg, 95%CI -1.4 to 4.0, p=0.35, I2=60%. Diastolic 
treatment effect for summer: 1.4mmHg, 95%CI -0.4 to 3.2, p=0.11, I2=38%; for winter 
0.8mmHg, 95%CI -0.1 to 1.6, p=0.07, I2=0%) 
 
Discussion 
Our analysis found no evidence of blood pressure reduction by vitamin D or vitamin D analogs, 
a result that was consistent between the trial-level and individual patient analyses. Subgroup 
analyses found no evidence of blood pressure reduction in patients with elevated baseline blood 
pressure or patients with diabetes mellitus; there was no relationship between the effect of 
supplementation on blood pressure and use of ACE inhibitors, baseline 25OHD levels, baseline 
blood pressure or baseline PTH level. The narrow confidence intervals around the main result 
suggest that a clinically significant reduction in blood pressure is unlikely based on the doses 
of vitamin D studied in this analysis; the lack of effect argues against a role for vitamin D 
supplementation either as a treatment for blood pressure control in individual patients, or as a 
population-based intervention to reduce blood pressure. These results are broadly consistent 
with previous meta-analyses9-11, although they contrast with the small reduction in blood 
pressure in trials with high baseline blood pressure found in our previous meta-analysis. Our 
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analysis however includes a much larger number of studies than previous analyses, and hence 
a larger number of patients and larger range of doses. Our use of individual patient data allowed 
us to examine whether particular subgroups might still benefit from vitamin D 
supplementation, which previous analyses have not been able to address. 
 
Although the number of included patients is greater than in previous meta-analyses, and the 
use of individual patient data have allowed analysis of subgroups, there remain limitations to 
this systematic review. Included studies are almost all single centre trials, and most are of 
modest size; none recruited >1000 patients. As a result, baseline imbalances between trials 
were common, and such imbalances are difficult to fully correct for, even with individual 
patient data analysis13. Not all studies were of high quality; deficiencies in intention-to-treat, 
reporting of masking and allocation concealment were noted. It is possible that not all eligible 
studies have been included, although our wide search strategy, contact with leading authors in 
the field, lack of language restriction and grey literature search would be expected to mitigate 
against this. Nevertheless, it is possible that other blood pressure data exists (e.g. from 
osteoporosis trials) that has not as yet been published and that we have been unable to locate63. 
A further limitation is the small number of trials which have specifically targeted patients with 
hypertension at baseline; such patients would perhaps be more likely to respond to 
antihypertensive interventions. We did not see an effect of vitamin D supplementation even in 
this subgroup, although the high level of background treatment with antihypertensives and 
other cardiovascular medications known to interact with vitamin D (e.g. statins) may again 
obscure detection of small treatment effects. 
 
Debate continues as to what level of 25OHD constitutes a biological optimum, and what level 
of vitamin D supplementation is necessary to achieve such levels. Levels of >75nmol/L have 
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been postulated as necessary for optimum health64, but such levels are based on observational 
data and do not necessarily indicate the level required for maximal antihypertensive effects. 
Levels of vitamin D supplementation required to reach such levels vary widely depending on 
age, sex, obesity and baseline 25OHD levels; doses from 1600 IU per day to over 5000 IU per 
day have been advocated as necessary65,66. Most doses studied in this review were at or below 
the lower end of this range, and several studies used intermittent dosing (weekly, monthly, or 
less frequent). Intermittent doses may have different biological effects67 when compared to 
smaller, regular doses; intermittent doses appeared less effective at reducing the incidence of 
respiratory infection in a recent systematic review68, although no such effect was evident for 
blood pressure reduction in our analysis. Although it is possible that larger, frequent doses of 
vitamin D might still have effects on reducing blood pressure, we found no evidence of a dose-
response relationship in our analyses. Further, most studies were in participants with European 
ancestry, and beneficial effects cannot be excluded in other ethnic groups although our 
subgroup analysis did not find evidence to support this. 
 
The results of this analysis add to the growing body of literature casting doubt on the ability of 
vitamin D supplementation to influence health outcomes beyond falls, fractures and possibly 
respiratory infection and all-cause mortality68,69. Recent analyses have shown that although 
observational data suggests an association between low 25OHD levels and cardiovascular 
events, diabetes and many cancers, intervention data do not support an effect across most of 
these diseases70. This may be in part because of the difficulty in fully disentangling low 25OHD 
levels from other, closely associated factors (e.g. ageing, obesity, smoking, inactivity) that 
affect both 25OHD levels and promote disease, but also in part that not all studies have targeted 
patients with the lowest circulating 25OHD levels. A further possibility is that 25OHD is a 
consequence, rather than a cause, of disease or disease precursor states; inflammatory 
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responses have been shown to acutely reduce 25OHD levels71, although whether chronic 
inflammation caused by subclinical disease can have the same effect is not known. It is also 
possible that vitamin D has beneficial actions on cardiovascular health that are not captured by 
office brachial artery blood pressure measurement, which has been argued to be less reliable 
than other measures, e.g. ambulatory blood pressure measurement or central aortic blood 
pressure measurement – although previous work suggests that central effects of 
antihypertensives may be smaller than effects on peripherally-measured blood pressure72. 
Alternative mechanisms of action of vitamin D such as alteration of endothelial function or 
markers of thrombogenicity have been postulated5,55, and trials examining vascular events as 
the primary outcome are still required to examine these possibilities. Such trials of vitamin D 
supplementation are now underway in Finland, New Zealand and USA, and the results of these 
trials should further clarify the position of vitamin D in the cardiovascular therapeutic 
armamentarium. Recent data from a large Mendelian randomisation study73 suggests that 
alleles linked to higher circulating 25OHD levels are associated with slightly lower systolic 
and diastolic blood pressure, and with a lower risk of hypertension. These findings are not 
inconsistent with our results however; Mendelian randomisation studies are predicated on the 
alleles in question having no effects on the vascular system other than their effect on 25OHD 
levels, which may not be the case for the alleles tested (cytochrome CYP21R and DHCR7, a 
cholesterol metabolising gene). Furthermore, differences in 25OHD levels seen in Mendelian 
randomisation studies are likely to have been present since birth given the genetic influences 
under test, and it is possible that exposure of the vascular tree to higher levels of 25OHD during 
development and in subsequent decades has small beneficial effects that cannot be replicated 
in shorter-term intervention studies. 
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In conclusion, the results from this analysis do not support the use of vitamin D analogs as an 
individual patient treatment for hypertension or as a population-level intervention to lower 
blood pressure.  
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Table 1. Trial level meta-analysis results 
Parameter N for trials N for 
participants 
Effect size (95% CI) p I2(%)  P between 
groups 
Systolic BP (mmHg) 
Overall 46 4541 0.0 (-0.8, 0.8) 0.97 21 - 
Mean baseline systolic >140mmHg 16 1361 -0.7 (-3.2, 1.7) 0.55 38 0.54 
Mean baseline systolic <=140mmHg  30 3180 0.1 (-0.6, 0.9) 0.77 11  
D2 and D3 38 4058 0.0 (-0.9, 0.9) 0.97 26 - 
1-alpha OHD 5 191 -1.6 (-6.3, 7.1) 0.50 4 0.64 
Paricalcitol 3 292 1.4 (-3.3, 6.1) 0.56 0 0.57 
Mean baseline 25OHD <=50nmol/L 27 2555 -0.7 (-2.2, 0.7) 0.31 38 0.31 
Mean baseline 25OHD >50nmol/L 13 1723 0.1 (-0.4, 0.6) 0.75 0  
Daily dosing 16 1522 -0.7 (-2.5, 1.0) 0.41 24 - 
Weekly / fortnightly dosing 8 1303 1.3 (-0.1, 2.6) 0.07 0 0.07 
>=Monthly dosing 14 1216 -0.2 (-1.6, 1.2) 0.76 28 0.66 
 
Diastolic BP (mmHg) 
28 
 
Overall 45 4434 -0.1 (-0.6, 0.5) 0.84 20 - 
Mean baseline systolic >140mmHg 14 1074 -0.4 (-2.1, 1.3) 0.61 55 0.65 
Mean baseline systolic <=140 mmHg 30 3180 0.0 (-0.4, 0.3) 0.85 0  
D2 and D3 37 3951 0.1 (-0.3, 0.5) 0.65 4 - 
1-alpha OHD 5 191 -3.5 (-6.8, -0.1) 0.04 54 0.04 
Paricalcitol 2 112 -1.0 (-3.9, 1.9) 0.50 0 0.46 
Mean baseline 25OHD 25-50nmol/L 26 2375 0.2 (-0.5, 1.0) 0.54 17 0.50 
Mean baseline 25OHD >50nmol/L 12 1616 -0.1 (-0.5, 0.4) 0.69 0  
Daily dosing 16 1466 -0.5 (-1.5, 0.4) 0.26 23 - 
Weekly / fortnightly dosing 8 1303 0.6 (-0.4, 1.5) 0.23 0 0.11 
>=Monthly dosing 14 1213 0.0 (-0.4, 0.5) 0.84 0 0.35 
25OHD: 25-hydroxyvitamin D 
  
29 
 
  
Table 2. Individual Patient Data meta-analysis results 
Systolic blood pressure n Effect size (95% CI) (mmHg) P I2 (%) P between 
groups 
Overall 3092 -0.5 (-1.3, 0.4) 0.27 0 - 
Baseline systolic BP >140mmHg 926 0.1 (-2.5, 2.6) 0.97 33 0.84 
Baseline systolic BP <=140mmHg 2148 -0.6 (-1.5, 0.3) 0.18 0  
Baseline 25OHD<25nmol/L 427 -0.4 (-3.0, 2.3) 0.80 14 - 
Baseline 25OHD 25-50nmol/L 1289 -0.7 (-2.0, 0.6) 0.31 0 0.83 
Baseline 25OHD >50nmol/L 1331 -0.2 (-1.8, 1.3) 0.77 26 0.95 
Diabetes mellitus 353 1.1 (-2.9, 5.1) 0.58 50 0.46 
No diabetes mellitus 2728 -0.4 (-1.3, 0.4) 0.35 0  
On ACEi 475 -1.4 (-3.7, 1.0) 0.24 1 0.31 
Not on ACEi 1485 0.1 (-1.4, 1.6) 0.94 29  
Baseline PTH>4.8pmol/L 1318 -0.8 (-2.1, 0.5) 0.23 0 0.76 
Baseline PTH<=4.8pmol/L 1364 -0.5 (-2.1, 1.2) 0.58 37  
Baseline adjusted serum calcium >2.31mmol/L 1267 -1.0 (-2.3, 0.4) 0.17 0 0.39 
Baseline adjusted serum calcium <=2.31mmol/L 1340 0.2 (-2.2, 2.6) 0.86 64  
30 
 
 Diastolic blood pressure n Effect size (95% CI) (mmHg) P I2 (%) P for 
interaction 
Overall 3075 0.2 (-0.3, 0.7) 0.38 0 - 
Baseline diastolic BP >90mmHg 315 -0.2 (-3.3, 2.9) 0.90 52 0.83 
Baseline diastolic BP <=90mmHg 2736 0.1 (-0.4, 0.7) 0.60 0  
Baseline 25OHD<25mmol/L 427 -1.2 (-2.4, 0.0) 0.05 46 - 
Baseline 25OHD 25-50nmol/L 1289 -0.2 (-1.0, 0.6) 0.66 0 0.11 
Baseline 25OHD >50nmol/L 1328 0.2 (-0.5, 0.9) 0.50 23 0.03 
Diabetes mellitus 342 1.2 (-0.1, 3.4) 0.28 36 0.32 
No diabetes mellitus 2722 0.1 (-0.4, 0.6) 0.81 0  
On ACEi 475 0.1 (-1.3, 1.5) 0.92 0 0.64 
Not on ACEi 1482 0.4 (-0.2, 1.1) 0.19 43  
Baseline PTH>4.8pmol/L 1324 0.0 (-0.8, 0.8) 0.99 0 0.80 
Baseline PTH<=4.8pmol/L 1362 0.2 (-0.7, 1.0) 0.70 10  
Baseline adjusted serum calcium >2.31mmol/L 1266 0.1 (-0.7, 0.9) 0.73 0 0.22 
Baseline adjusted serum calcium <=2.31mmol/L 1340 1.1 (-0.3, 2.4) 0.12 54  
 
ACEi: Angiotensin converting enzyme inhibitor. 25OHD: 25-hydroxyvitamin D. PTH: Parathyroid hormone 
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Figure legends: 
 
 
Figure 1. PRISMA diagram of study selection 
 
Fig 2. Results of trial-level meta-analysis (panel a = systolic, panel b = diastolic) 
 
Fig 3. Results of Individual Patient Data analysis (using final BP adjusted for baseline BP) (panel a = systolic, panel b = diastolic) 
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eTable 1. Characteristics of included studies 
Study N Latitu
de 
Study 
Population 
Outcomes Mean 
Age 
% 
Male 
Mean 
baseline 
25OHD 
(nmol/l) 
Mean 
baseline 
SBP 
(mmHg) 
Control Intervention Duration 
Lind et al1, 
Sweden, 1987 
29 60° N Healthy 
volunteers with 
intermittent 
hypercalcaemia 
Blood pressure 63 40 Not 
known 
149 Placebo Alphacalcidol 1 µg/day 6 months 
Lind et al2, 
Sweden, 
1988a 
36 61° N Patients with 
primary 
hyperparathyroi
dism 
Blood pressure 65 19 Not 
known 
149 Placebo Alphacalcidol (0.25 µg/day up-titrated 
to 1 µg/day after 8 weeks) 
6 months 
Lind et al3, 
Sweden, 
1988b 
65 60° N Patients with 
impaired 
glucose 
tolerance 
Blood pressure 
and glucose 
tolerance 
Not 
stated 
100 Not 
known 
152 Placebo Alphacalcidol 0.75µg/day 12 weeks 
Lind et al4, 
Sweden, 1989 
42 61° N Patients with 
mild to 
moderate 
hypertension 
Blood pressure 
and plasma 
renin activity 
51 80 Not 
known 
157 Placebo Alphacalcidol 1µg/day 18 weeks 
Myrup et al5, 
Denmark, 
1992 
113 56° N Elderly female 
patients 
Blood pressure, 
cholesterol, 
weight 
70 0 Not 
known 
101 
(MAP) 
Placebo Calcitriol 0.5µg/day 12 months 
Pan et al6, 
Taiwan, 1993 
58 25° N Institutionalised 
adults 
Blood pressure 74 78 61 133 Placebo Cholecalciferol 200IU/day + placebo 11 weeks 
Scragg et al7, 
England, 1995 
191 52° N Elderly patients Blood pressure, 
cholesterol 
70 54 35 148 Placebo Cholecalciferol 100,000IU once-off 5 weeks 
34 
 
Pfeifer et al8, 
Germany, 
2001 
148 52° N Elderly female 
patients 
Blood pressure, 
cholesterol 
75 0 25 142 Calcium 
1200mg/daily 
+Placebo 
Calcium 1200mg/ daily  + 
Cholecalciferol 800IU/day 
8 weeks 
Schleithoff et 
al9, Germany, 
2006 
123 51° N Heart failure 
patients 
Blood pressure, 
cytokine levels, 
survival 
55 83 38 
(median
) 
123 Calcium 
500mg 
once/daily + 
placebo 
Calcium 500mg/ once daily  + 
Cholecalciferol  2000IU/day 
9 months 
Alborzi et 
al10, USA, 
2008 
24 40° N Patients with 
chronic kidney 
disease and on 
ACE-I or ARB 
Endothelial 
function, 24 
hour ambulatory 
BP, GFR, CRP 
70 83 34 125.4 
(24hr 
BP) 
Placebo Paricalcitol 1µg daily 
Paricalcitol 2µg daily 
1 month 
Sugden et al11, 
Scotland, 
2008 
34 56 ° N Type 2 Diabetes 
patients 
Endothelial 
function, blood 
pressure, insulin 
sensitivity 
64 53 38 141 Placebo Ergocalciferol 
100,000IU single dose 
 
8 weeks 
Nagpal et al12, 
India, 2009 
100 28° N Centrally obese, 
non-diabetic, 
healthy males 
Insulin 
sensitivity, 
insulin 
secretion, lipid 
concentration, 
blood pressure 
44 100 33 124 Placebo Cholecalciferol 120,000IU /2 weekly 6 weeks 
Zittermann et 
al13, Germany, 
2009 
200 52° N Healthy 
overweight 
subjects 
participating in 
weight 
reduction 
program 
Weight loss, 
cardiovascular 
disease risk 
markers 
including blood 
pressure 
48 33 30 128 Placebo Cholecalciferol 3332 IU/day 12 months 
Jorde et al14, 
Norway, 2010 
438 69° N Overweight or 
obese subjects 
Cardiovascular 
risk factors 
48 36 58 124 Placebo + 
500mg 
calcium/day 
Cholecalciferol 20,000 IU weekly + 
500mg calcium/day 
12 months 
35 
 
without diabetes 
or IHD 
 
Cholecalciferol 40,000 IU weekly + 
500mg calcium/day 
Witham et 
al15, Scotland, 
2010a 
61 56° N Type II 
Diabetes and 
baseline 
Vitamin D 
<100nmol/l 
Endothelial 
function, blood 
pressure, 
markers of 
glycaemic 
control 
65 67 45 146 Placebo 100,000 IU  Cholecalciferol 
200,000 IU cholecalciferol single dose 
16 weeks 
Witham et 
al16, Scotland, 
2010b 
105 56° N Older adults 
with heart 
failure 
Walk test, 
physical 
activity, 
cardiovascular 
and 
inflammatory 
markers, blood 
pressure 
80 66 22 141 Placebo Ergocalciferol 100,000 IU 10 weekly. 20 weeks 
de Zeeuw et 
al17, 
Multinational, 
2010 
281 Multin
ational 
Patients with 
Type II diabetes 
and albuminuria 
receiving 
ACEi/ARBs 
Albuminuria, 
eGFR, blood 
pressure 
64 65 41 142 Placebo Paricalcitol 1µg daily 
Paricalcitol 2µg daily 
24 weeks 
Harris et al18, 
USA, 2011 
45 33° N African-
American 
Adults with no 
overt 
cardiovascular, 
pulmonary or 
metabolic 
disease 
Endothelial 
function, 
anthropometric 
assessments, 
blood pressure 
30 47 36 124 Placebo Cholecalciferol 60,000IU/ 4 weekly 16 weeks 
36 
 
Shab-Bidar  et 
al19, Iran 2011 
100 36° N Non-insulin 
requiring Type 
II Diabetes 
Mellitus 
Glycaemic 
status, lipid 
profile and 
endothelial 
biomarkers 
53 
 
43 38 127 Plain Yoghurt 
Drink with 
170mg/ 
calcium twice 
a day 
Cholecalciferol fortified yoghurt drink 
170mg/calcium and 500IU/250ml 
twice daily 
12 weeks 
Alvarez et 
al20, USA, 
2012 
48 34° N Early chronic 
kidney disease 
Vitamin D 
status, 
circulating PTH 
concentrations 
62 95 74 129 Placebo Cholecalciferol 50,000 IU/ week for 12 
weeks then 50,000 IU every other week 
for 40 weeks. 
12 months 
Bonakdaran et 
al21, Iran, 
2012 
51 35° N Untreated 
Polycystic 
Ovarian 
syndrome 
Patients 
Improvement in 
ovulation, 
insulin 
resistance, 
blood pressure 
25 0 51 110 Placebo Metformin 1g/day; 
Calcitriol 0.5µg/day 
 
3 months 
Gepner et al22, 
USA, 2012 
114 43° N Healthy 
community 
dwelling 
postmenopausal 
females with 
serum vitamin 
D >10 and 
<60ng/ml 
Endothelial 
function (pulse 
wave velocity, 
flow mediated 
dilatation, 
augmentation 
index) 
64 0 78 119.4 Placebo Cholecalciferol 2500 IU/day 4 months 
Heshmat et 
al23, Iran, 
2012 
42 36° N Type II 
Diabetes 
Mellitus 
Insulin 
resistance and 
anthropometric 
factors 
56 36 103 119 Placebo Cholecalciferol 
300,000IU once-off 
3 months 
Kjaergaard et 
al24, Norway, 
2012 
243 69° N Adults aged 30-
75 years 
Depressive 
symptoms, 
53 44 48 129 Placebo Cholecalciferol 40,000 IU once weekly 6 months 
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Larsen et al25, 
Denmark,201
2 
130 56° N Caucasian 
hypertensive 
patients 
Blood pressure, 
arterial stiffness 
61 31 58 143 Placebo Cholecalciferol 3000 IU/day 20 weeks 
Longenecker 
et al26, 2012, 
USA 
45 42° N Vitamin D 
deficient HIV 
infected adults 
Endothelial 
function 
45 78 21 118 Placebo Cholecalciferol 4000 IU daily 12 weeks 
Muldowney et 
al27, Ireland 
2012a 
209 51-55° 
N 
Older adults 
aged >64 years 
during winter 
Biomarkers of 
cardiovascular 
disease risk 
71 40 54 146 Placebo Cholecalciferol 200 IU per day or 400 
IU per day or 600 IU per day 
22 weeks 
Muldowney et 
al27, Ireland 
2012b 
233 51-55° 
N 
Young adults 
aged 20-40 
years during 
winter 
Biomarkers of 
cardiovascular 
disease risk 
30 51 70 124 Placebo Cholecalciferol 200 IU per day or 400 
IU per day or 600 IU per day 
22 weeks 
Salehpour et a 
28, Iran, 2012 
85 36° N Healthy 
premenopausal 
overweight and 
obese women 
Blood pressure, 
lipid profile, 
anthropometric 
parameters 
38 0 42 113.5 Placebo Cholecalciferol 1000 IU/day 90 days 
Stricker et 
al29, 
Switzerland, 
2012 
62 46° N Chronic 
peripheral 
vascular disease 
and vitamin D 
deficiency 
Endothelial 
function and 
arterial stiffness, 
coagulation and 
inflammation 
parameters. 
74 61 42 137 Placebo Cholecalciferol (Vitamin D3) 100,000 
IU single dose 
1 month 
Witham et 
al30, Scotland, 
2012 
58 56° N Older adults 
with previous 
stroke 
Blood pressure, 
endothelial 
function 
67 72 38 128 Placebo 100,000 IU Ergocalciferol 16 weeks 
Wood et al31, 
Scotland, 
2012 
305 57° N Healthy 
Postmenopausal 
women aged 60-
70 years 
Lipid profile, 
insulin 
resistance, 
inflammatory 
64 0 34 128.5 Placebo 400 IU/day  Cholecalciferol  
1000 IU/day Cholecalciferol 
 
1 year 
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biomarkers, 
blood pressure 
Asemi et al32, 
Iran, 2013 
54 34° N Pregnant 
women in Iran 
C-Reactive 
Protein, Insulin 
resistance and 
biomarkers of 
oxidative stress 
25 0 40 112 Placebo 
+ 400µg/day 
folic acid + 60 
µg/day iron 
Cholecalciferol 400 IU/day + 
400µg/day folic acid + 60 µg/day iron 
9 weeks 
Boxer et al33, 
USA, 2013 
64 41° N Over 50 year 
olds with heart 
failure and 
vitamin D 
deficiency 
Cardiopulmonar
y stress testing 
66 52 46 116 Placebo once 
weekly + 
Calcium 
Citrate 400mg 
twice daily 
Cholecalciferol 50,000 IU weekly + 
Calcium Citrate 400mg twice daily 
6 months 
Breslavsky et 
al34, Israel, 
2013 
47 32° N Type II 
Diabetics with 
cardiovascular 
risk factors 
Arterial 
properties, 
adiponectin, 
leptin and 
glucose 
homeostasis 
66 47 30 153 Placebo Cholecalciferol 1000 IU/day 12 months 
Chai et al35, 
USA, 2013 
92 21° N 30 – 75 year 
olds with 
adenomatous 
colorectal polys 
Blood pressure, 
serum lipids and 
carotenoids 
61 70 Not 
known 
126 Placebo Calcium carbonate 2g/day OR 
Cholecalciferol 800 IU/day OR 
Calcium carbonate 2g/day + 
Cholecalciferol 800 IU/day 
6 months 
Forman et 
al36, USA, 
2013 
283 42° N Healthy Black 
Population 
Systolic and 
diastolic blood 
pressure 
51 35 39 122 Placebo 
+200mg 
calcium daily 
Cholecalciferol 1000 IU/day or 2000 
IU/day or 4000 IU/day all + 200mg 
calcium daily 
3 months 
Larsen et al37 
2013, 
Denmark 
30 56° N Non-diabetic, 
albuminuric 
stage II-IV 
chronic kidney 
disease 
Plasma renin 
concentration, 
albuminuria 
61 73 56 136 Placebo Paricalcitol 2 µg daily 6 weeks 
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Petchey et 
al38, Australia, 
2013  
28 28° S Chronic Kidney 
Disease Stage 3-
4 
Insulin 
resistance 
66 71 91 135 Placebo Cholecalciferol 2000IU daily 6 months 
Roth et al39, 
Bangladesh, 
2013 
160 24° N Third trimester 
of pregnancy 
Vitamin D 
status 
22 0 45 104 Placebo 
 
 
Cholecalciferol 35,000 IU weekly Mean 10 
weeks 
Toxqui et al40, 
Spain, 2013 
129 40° N Healthy 18-35 
year old 
Caucasian 
women 
Iron and bone 
metabolism 
biomarkers, 
blood pressure, 
glucose and 
lipid levels 
25 0 63 109 15mg Iron-
fortified dairy 
product 
15mg iron fortified dairy product and 
200 IU cholecalciferol daily 
16 weeks 
Wamberg et 
al41, Denmark, 
2013 
55 56° N Obese subjects 
aged 18-50years 
with low 
vitamin D levels 
Obesity related 
complications 
such as chronic 
low grade 
inflammation, 
insulin 
resistance, 
hypertension 
and 
hyperlipidaemia 
40 29 35 133 Placebo Cholecalciferol 7000 IU/day 26 weeks 
Witham 2013 
et al42, 
Scotland, 
2013a 
159 56° N Isolated systolic 
hypertension in 
over 70 year 
olds 
Blood pressure, 
Endothelial 
function 
77 52 45 163 Placebo Cholecalciferol 100,000 IU three 
monthly 
12 months 
Witham et 
al43, Scotland, 
2013b 
75 56 ° N Recent 
myocardial 
infarction 
patients 
Endothelial 
function, blood 
pressure, 
cholesterol 
66 69 47 127.5 Placebo Cholecalciferol 100,000IU/ 2 monthly 6 moths 
40 
 
Witham et 
al44, Scotland, 
2013c 
50 56° N South-east 
Asian women 
living in UK for 
10 years 
Macrovascular 
and 
microvascular 
endothelial 
function 
41 0 27 120 Placebo Cholecalciferol 100,000 IU once off 8 weeks 
Yiu et al45, 
Hong Kong 
2013 
100 22° N Type II diabetes 
mellitus with 
suboptimal 
vitamin D status 
Endothelial 
function, 
endothelial 
progenitor cells, 
CRP 
65 50 54 146 Placebo Cholecalciferol 5000 IU daily 12 weeks 
Dalbeni et 
al46, Italy, 
2014` 
36 45° N Chronic heart 
failue aged >40 
years 
Ejection 
fraction and 
echocardiograph
y parameters 
72 74 44 133 Placebo Cholecalciferol 600,000 IU at baseline, 
100,000 IU at 10 weeks and 20 weeks 
6 months 
Scragg et al47, 
New Zealand, 
2014 
322 44° S Healthy adults Number and 
severity of 
upper 
respiratory tract 
infections 
48 25 71 123 Placebo Cholecalciferol 200000 IU first month, 
200000 IU second month then 100000 
IU monthly 
18 months 
Sollid et al48, 
Norway, 2014 
511 70° N Prediabetes Glucose 
metabolism and 
cardiovascular 
risk factors 
62 61 61 135 Placebo Cholecalciferol 20000 IU weekly 12 months 
Strobel et al49, 
Germany 
2014 
86 50° N Non-insulin 
requiring Type 
II Diabetes 
Mellitus 
Insulin 
resistance and 
blood glucose 
levels 
60 56 36 141 Placebo Cholecalciferol 1904IU/day Once 
Weekly 
6 months 
Wang et al50, 
Hong Kong, 
2014 
60 23° N Stage 3-5 non-
dialysis CKD 
with left 
Change in Left 
Ventricular 
mass index 
61 53 Not 
known 
133 Placebo Paricalcitol – if iPTH<500pg/ml 
Paricalcitol 1µg 
If iPTH >500pg/ml Paricalcitol 2µg 
12 months 
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ventricular 
hypertrophy 
Witham et 
al51, Scotland, 
2014 
68 56° N Resistant 
hypertension 
Blood pressure, 
glucose, 
cholesterol and 
Left ventricular 
mass index 
63 65 42 154 Placebo Cholecalciferol 100,000 IU every 2 
months 
6 months 
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 eTable 2: Risk of bias table for all included studies  
 
Study Quality of 
allocation 
concealment 
Analysis on 
intention to 
treat 
Number and 
description of 
dropouts 
Blinding – 
patients 
Blinding – health 
care providers 
Blinding – 
outcome 
assessors 
Comparable 
treatment and 
placebo groups 
Lind 1987 1 + U + U U U - 
Lind 1988a 2 + + + + + U + 
Lind 1988b 3 + U _ + + + - 
Lind 1989 4 + + + + + U + 
Myrup 1992 5 + U - + + + + 
Pan 1993 6 + - + + + + - 
Scragg 1995 7 + + + + + + + 
Pfeifer 2001 8 + + + + + + + 
Schleithoff 2006 9 + - + + + + + 
Alborzi 2008 10 + + + + + + - 
Sugden 2008 11 + - + + + + + 
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Nagpal 2009 12 + + + + + + + 
Zittermann 2009 13 + U + + + + + 
Jorde 2010 14 + - + + + + + 
Witham 2010a 15 + U + + + + + 
Witham  2010b 16 + + + + + + + 
de Zeeuw 2010 17 + + + + + + + 
Harris 2011 18 + U + + + + + 
Shab-Bidar 2011 19 + - + + + + + 
Alvarez 2012 20 + + + + + + + 
Bonakdaran 2012 21 - - + U U U - 
Gepner 2012 22 + + + + + + + 
Heshmat 2012 23 + U + + + + - 
Kjærgaard 2012 24 + - + + + + + 
Larsen 2012 25 + - + + + + + 
Longenecker 2012 26 + U + + + + + 
Muldowney 2012a 27 + - + + + + + 
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Muldowney 2012b 27 + - + + + + + 
Salehpour 2012 28 + U + + + + - 
Stricker 2012 29 + + + + + + - 
Witham 2012 30 + U + + + + + 
Wood 2012 31 + + + + + + + 
Asemi 2013 32 + - + + + - + 
Boxer 2013 33 + + + + + + + 
Breslavsky 2013 34 + - + U U U + 
Chai 2013 35 + U + + + + - 
Forman 2013 36 + + + + + + - 
Larsen 2013 37 + - + + + + U 
Petchey 2013 38 + - + + + + - 
Roth 2013 39 + + + + + + + 
Toxqui 2013 40 + - + + + + + 
Wamberg 2013 41 + + + + + + + 
Witham 2013a 42 + - + + + + + 
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Witham 2013b 43 + + + + + + + 
Witham 2013c 44 + + + + + + + 
Yiu 2013 45 + + + + + + + 
Dalbeni 2014 46 + - - + + + - 
Scragg 2014 47 + + + + + + + 
Sollid 2014 48 + - + + + + + 
Strobel 2014 49 + - + + + + + 
Wang 2014 50 + + + + + + + 
Witham 2014 51 + + + + + + + 
 
+ Adequate / yes, - Inadequate / no, U: Unclear 
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eAppendix: Search strategy for D-PRESSURE systematic review 
 
[vitamin D OR vitamin D2 OR vitamin D3 OR cholecalciferol OR ergocalciferol OR alphacalcidol OR alfacalcidol OR calcitriol OR paricalcitol 
OR doxerocalciferol] 
 
AND 
 
[randomised controlled trial OR placebo] 
 
AND 
 
[blood pressure OR hypertension OR vascular OR cardiovascular OR mortality] 
 
Applied to all fields within database; not restricted to MeSH headings 
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eFigure 1. Funnel plot for trial-level systolic blood pressure treatment effects 
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eFigure 2: Meta-regression of treatment effect vs mean trial-level baseline systolic blood pressure 
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